Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field

  • Poseida Therapeutics Inc PSTX has entered into a strategic collaboration and license agreement with Roche Holdings AG RHHBY, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. 
  • The collaboration covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas, and other hematologic indications.
  • Under the agreement, Roche will receive from Poseida either exclusive rights or options to develop and commercialize several allogeneic CAR-T programs in Poseida's portfolio.
  • Poseida's P-BCMA-ALLO1, an allogeneic CAR-T for multiple myeloma, is in Phase 1 study, and P-CD19CD20-ALLO1, an allogeneic dual CAR-T for B-cell malignancies with an IND, expected in 2023.
  • For a subset of the Poseida portfolio programs licensed or optioned to Roche, Poseida will conduct the Phase 1 studies and manufacture clinical materials before transitioning the programs to Roche for further development and commercialization. 
  • Roche will be solely responsible for the late-stage clinical development and global commercialization.
  • Poseida will receive $110 million upfront and could receive up to $110 million in near-term milestones.
  • In addition, Poseida is eligible to receive up to $6 billion in milestone payments.
  • Price Action: PSTX shares are up 60.10% at $3.89 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!